

Biomarkers And Screening Tests For Abdominal Aortic Aneurysm: A Brief Review

R Meenakshisundaram, P Thirumalaikolundusubramanian

Citation

R Meenakshisundaram, P Thirumalaikolundusubramanian. *Biomarkers And Screening Tests For Abdominal Aortic Aneurysm: A Brief Review*. The Internet Journal of Cardiovascular Research. 2008 Volume 6 Number 1.

Abstract

Background: Abdominal aortic aneurysm (AAA), though it is a deadly disease, it remains silent invariably. Hence, one has to suspect and evaluate AAA at least in a susceptible group at an earlier stage to reduce the morbidity and mortality.

Objective: To find out the usefulness and limitations of various biomarkers in diagnosing AAA and drug to prevent/treat it.

Material And Methods: Published data were collected from web using keywords biomarkers, clinical methods, screening tests and abdominal aortic aneurysm.

Results: Biomarkers identified for AAA are osteopontin (OPN), osetoprotegrin (OPG), Matrix metalloproteinase-9 (MMP-9), circulating levels of tumor necrosis factor- α , interleukin-1 α , interleukin -6, interferon- γ , amino terminal propeptide of type 3 collagen, C-reactive protein (CRP), fibrinogen, total WBC count, albumin and ultrasonogram of abdomen. Co-existing illnesses influence inflammatory biomarkers. The promising biomarker is Osteopontin and this is useful to assess the status and progression of AAA. The drug, Irbesartan (angiotensin II blocker) has been shown to reduce the size of aneurysm by dwindling the secretion of osteoprotegrin.

Conclusions: Primary focus should be on early detection and management. To achieve this goal, orientation of primary health care professionals towards symptoms and signs of AAA, surgeons to look for the same during abdominal surgeries and radiologists to search for it during USG/ CT scan of abdomen.

*This paper was presented in the conference "SUMMIT ON ACUTE AORTIC DISEASES: LUX ET VERITAS" held at Yale University Medical School, New Haven, Connecticut, USA on November 1-2, 2007. This program was conducted by Promedica International CME, a California corporation.

INTRODUCTION

Biomarkers are used to indicate or measure biological processes. An example of this is, levels of a specific protein in body fluid, genetic mutations or brain abnormalities observed in a PET scan or other imaging tests. Detecting biomarkers specific to a disease can aid in the identification, diagnosis, treatment and follow up of affected individuals and people who may be at risk but do not exhibit symptoms. Abdominal aortic aneurysm (AAA) is often asymptomatic¹ and causes considerable mortality and morbidity^{1,2}. Risk factors for AAA include increasing age, male gender, smoking, coronary heart disease, hypertension, dyslipidemia, positive family history^{3,4,5} and prolonged steroid intake⁶. Various modalities such as physical examination^{7,8}, biomarkers^{9,10,11,12} and imaging studies^{7,8} can be used to

diagnose at earlier stages. Physical examination is inexpensive, but lacks sensitivity and specificity^{7,13} and accuracy largely depends on skill of the examiner and the aneurysm size⁷. Imaging studies such as CT scan and MRI have high yield in its diagnosis but cost limits its use^{7,8}. Hence, a brief review was made to find out the usefulness and limitations of various biomarkers in diagnosing AAA and pharmacological agent which could treat/prevent aneurysms.

MATERIAL AND METHODS

This study was carried out in Madras Medical College, Chennai, India during the period of May 2007 to August 2007. We have collected published literature on AAA from the year 1995 to 2007 through the web by using keywords biomarkers, clinical methods, screening tests and abdominal aortic aneurysm.

RESULTS AND DISCUSSION

Biomarkers identified for AAA are osteopontin (OPN)¹⁴, osetoprotegrin (OPG)¹¹, Matrix metalloproteinase-9

(MMP-9)^{15,16,17,18,19}, circulating levels of tumor necrosis factor- α , interleukin-1 α , interleukin -6, interferon- γ , amino terminal propeptide of type 3 collagen^{20,21,22,23}, C-reactive protein (CRP), fibrinogen, total WBC count, albumin¹² and ultrasonogram of the abdomen^{7,8}.

Osteopontin is a phosphorylated acidic glycoprotein of molecular mass 44 kDa and has a role in promoting inflammation, proteolysis and atherosclerosis, which are all integral processes in AAA. The process is induced by a number of mechanisms including supporting macrophages, T cell chemotaxis and adhesion, prolonging lymphocyte survival, enhancing cell mediated immunity and activation of proteolytic pathways. Serum OPN level was significantly elevated in patients with AAA independent of other risk factors. It is also useful to assess status and progression of AAA¹⁴.

Osteoprotegrin, a member of tumor necrosis factor receptor family of member 11b; belongs to functional category of cytokine with Tnfrsf11b as a symbol. Its properties includes molecular weight of 45923, isoelectric point of 8.68, extinction coefficient of $48660\text{M}^{-1}\text{cm}^{-1}$, absorption coefficient of 1.06 and aliphatic index of 79.93. It is involved in pathogenesis of AAA and atherosclerosis. Serum concentration of OPG was weakly

correlated with aneurysm size and its secretion was abrogated by angiotensin II blocker. Hence, Irbesartan (angiotensin II blocker) has potential benefit in slowing aneurysm expansion¹¹. Since irbesartan has been shown to revert AAA to some extent, it is likely that the early use of irbesartan in susceptible population may avert the onset of development of AAA as well as aneurysm elsewhere in the arterial tree. However, the action of drug in the process of reversal or prevention is yet to be identified.

MMP-9 is the most abundant elastolytic proteinase secreted by human AAA tissues where it plays a vital role in connective tissue destruction and actively produced by aneurysm infiltrating macrophages at the site of tissue damage^{17,18}. MMP-9 expression appears to correlate with increasing aneurysm diameter¹⁹ and its plasma level is elevated in patients with AAA^{15,16}. According to Hovsepian¹⁵ et al., plasma level of MMP-9 decreased substantially after aneurysm repair.

Several other biomarkers such as circulating levels of tumor necrosis factor- α , interleukin-1 α , interleukin -6, interferon- γ and amino terminal propeptide of type 3 collagen have been

explored^{20,21,22,23}. Because many of these proteins are found in higher plasma concentrations in patients with atherosclerotic vascular disease and chronic inflammatory conditions, they have all proved to be nonspecific for aortic aneurysm.

Other biomarkers such as CRP, total WBC count, fibrinogen and albumin are used to distinguish asymptomatic and symptomatic, intact and rupture AAA¹². Abdominal ultrasound scanning is the best recommended screening test for AAA in our hospital and elsewhere^{7,8}. Screening of AAA reduces overall medical costs^{24,25} and mortality^{7,25}. There was a significant difference observed in cost effectiveness and mortality benefit between elective and emergency surgical repair of AAA²⁶.

Numerous variations were observed in screening protocols. According to MASS²⁷, men of age 65 to 74 years should be screened quarterly if the size of the AAA is 4.5 to 5.4 cm and annually if the size is 3 to 4.4 cm. Frame et al²⁸., suggested to have one follow up at every 5 years for men aged between 60 and 80 years. One time quick screen by ultrasonography of abdomen for men aged 70 was recommended by Lee et al²⁹.

Our primary focus should be on early detection and management. To achieve this goal, primary health care professionals should be trained to search for symptoms and signs of AAA during regular check-ups and surgeons be motivated to look for the same while doing abdominal surgeries³⁰, should look for AAA. In more than 50% of cases, femoral and popliteal aneurysms are associated with AAA³¹ and hence, radiologist must undertake abdominal scanning to identify peripheral artery aneurysms in lower extremities³². Further research is needed to assess the usefulness of ACE inhibitors/other angiotensin II blocker drugs for prevention/treatment of aneurysm.

References

1. Puech-Leao.P, Molnar LJ, De Oliveira IR, Cerri GG. Prevalence of abdominal aortic aneurysms- a screening program in Sao Paulo, Brazil. Sao Paulo Med.J 2004; 122 (4)
2. Gillum RF. Epidemiology of aortic aneurysm in the United States. J Clin Epidemiol. 1995; 48: 1289-1298.
3. Lederle FA, Johnson GR, Wilson SE, et al., Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med. 1997; 126: 441-449.
4. Alcorn HG, Wolfson SK, Jr., Sutton-Tyrrell K, Kuller LH, O'Leary D. Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol.1996; 16: 963-970.

5. Jamrozik K, Norman PE, Spencer CA, Parsons RW, Tuohy R, Lawrence-Brown MM, et al., Screening for abdominal aortic aneurysm: lessons from a population-based study. *Med J Aust.*2000; 173: 345-350.
6. National Library for Health (NLH). Should patients on oral steroids be screened for aortic aneurysm? Is there an association between oral steroids and large vessel abnormalities?. Primary care question answering service. 2006. Accessed online <http://www.clinicalanswers.nhs.uk/index.cfm?question=2058>.
7. Latif AA, Almahameed A, Lauer MS. Should we screen for Abdominal Aortic Aneurysm? Accessed online http://www.ccjm.org/PDFFILES/Latif1_06.pdf.
8. Isselbacher EM. Thoracic and abdominal aortic aneurysms. *Circulation.*2005; 111: 816-828.
9. Norman P, Spencer CA, Lawrence-Brown MM, Jamrozik K. C-reactive protein levels and the expansion of screen-detected abdominal aortic aneurysms in men. *Circulation.*2004; 110: 862-866.
10. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. *Arterioscler Thromb Vasc Biol.*2006; 26: 987-994.
11. Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. *Circulation.*2005; 111: 3119-3125.
12. Tambyraja AL, Dawson R, Valenti D, Murie JA, Chalmers RT. Systemic inflammation and repair of abdominal aortic aneurysm. *World Journal of Surgery.*2007;31 (6): 1212-1216.
13. Lederle FA, Simel DL. The rational clinical examination: does this patient have abdominal aortic aneurysm? *JAMA.*1999; 281: 77-82.
14. Golledge J, Muller J, Shephard N, et al., Association between osteopontin and human abdominal aortic aneurysm. *Arterioscler Thromb Vasc Biol.*2007; 27: 655.
15. Hovsepian DM, Ziporin SJ, Sakurai MK, et al., Elevated Plasma Levels of Matrix Metalloproteinase-9 in Patients with Abdominal Aortic Aneurysms: A Circulating Marker of Degenerative Aneurysm Disease. *Journal of Vascular and Interventional Radiology* 2000; 11: 1345-1352.
16. McMillan WD, Pearce WH. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. *J.Vasc.Surg* 1999; 29: 122-127.
17. Thompson RW, Holmes DR, Mertens RA, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms: an elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. *J Clin Invest* 1995; 96: 318-326.
18. McMillan WD, Patterson BK, Keen RR, Shively VP, Cipollone M, Pearce WH. In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta. *Arterioscler Thromb Vasc Biol* 1995; 15: 1139-1144.
19. McMillan WD, Tamarina NA, Cipollone M, Johnson DA, Parker MA, Pearce WH. Size matters: the relationship between MMP-9 expression and aortic diameter. *Circulation* 1997; 96: 2228-2232.
20. Satta J, Juvonen T, Haukipuro K, Juvonen M, Kairaluoma MI. Increased turnover of collagen in abdominal aortic aneurysms, demonstrated by measuring the concentration of the aminoterminal propeptide of type III procollagen in peripheral and aortal blood samples. *J Vasc Surg* 1995; 22: 155-160.
21. Satta J, Haukipuro K, Kairaluoma MI, Juvonen T. Aminoterminal propeptide of type III procollagen in the follow-up of patients with abdominal aortic aneurysms. *J Vasc Surg* 1997; 25: 909-915.
22. Juvonen J, Surcel HM, Satta J, et al. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. *Arterioscler Thromb Vasc Biol* 1997; 17: 2843-2847.
23. Rohde LE, Arroyo LH, Rifai N, et al. Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. *Arterioscler Thromb Vasc Biol* 1999; 19: 1695-1699.
24. Ishikawa S, Takahashi T, Sato Y, et al., Screening cost for abdominal aortic aneurysms: Japan-based estimates. *Surgery today.*2004; 34 (10): 828-831.
25. Meenan RT, Fleming C, Whitlock EP, Beil TL, Smith P. Cost-effectiveness analyses of population-based screening for abdominal aortic aneurysm: evidence synthesis. U.S. Preventive Services Task Force 1996.
26. Bagia JS, Robinson D, Kennedy M, Englund R, Hanel K. The cost of elective and emergency repair of AAA in patients under and over the age of 80. *ANZ Journal of Surgery.*1999; 69 (9): 651-654.
27. Multicentre Aneurysm Screening Study Group. Multicentre aneurysm screening study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from a randomized controlled trial. *BMJ* 2002; 325: 1135-8.
28. Frame PS, Fryback DG, Patterson C. Screening for abdominal aortic aneurysm in men ages 60 to 80 years. A cost-effectiveness analysis. *Ann Intern Med.*1993; 119 (5): 411-6.
29. Lee TY, Korn P, Heller JA, et al., The cost-effectiveness of a quick-screen program for abdominal aortic aneurysms. *Surgery.*2002; 132 (2): 399-407.
30. Barchiche R, Bove T, Demanet H, Goldstein JP, Deuvaert FE. Traumatic pseudoaneurysm of the abdominal aorta. *Acta chir belg,* 1999; 99: 174-176.
31. Family practice notebook. Surgery; cardiovascular medicine; AAA. Accessed online through <http://www.fpnotebook.com/SUR2.htm> on Dec 11, 2007.
32. Wolf YG, Otis SM, Schwend RB, Bernstein EF, Krupski WC. Screening for abdominal aortic aneurysms during lower extremity arterial evaluation in the vascular laboratory: Discussion. *J.vasc.surg.*1995; 22(4): 417-423.

Author Information

Ramachandran Meenakshisundaram, MBBS
Madras Medical College

Ponniah Thirumalaikolundusubramanian, MD
Madras Medical College